Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
14
×
Tags
life sciences
national blog main
national top stories
raleigh-durham blog main
14
×
raleigh-durham top stories
roche
14
×
san francisco blog main
san francisco top stories
boston blog main
boston top stories
national
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
detroit blog main
detroit top stories
biotech
boulder/denver blog main
boulder/denver top stories
cancer
indiana blog main
indiana top stories
clinical trials
pfizer
merck
amgen
deals
fda
startups
bristol-myers squibb
drugs
glaxosmithkline
immunotherapy
What
roundup
bio
cancer
drug
annual
medical
society
clinical
conference
crispr
oncology
today
ahead
american
asco
ash
big
blood
ceo
companies
company
data
days
esmo
european
fda
latest
life
lung
medicine
meeting
new
patients
plan
pricing
time
acquisitions
admits
advanced
advantages
Language
unset
unknown
Current search:
roche
×
photo
×
" raleigh-durham blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More